Hexaware Positioned as a Visionary in the 2026 Gartner® Magic Quadrant™ for Custom Software Development Services
Hexaware Positioned as a Visionary in the 2026 Gartner® Magic Quadrant™ for Custom Software Development Services
Gartner, Magic Quadrant for Custom Software Development Services, By Jaideep Thyagarajan, Ryan McKinney, Nathan Davie, 7 October 2026. Gartner and Magic Quadrant are trademarks of Gartner, Inc. and/or its affiliates. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose. This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available upon request from Hexaware.
Case Study
Streamlining supply chains to accelerate patient impact
Our client, a forward-thinking biotech firm, was preparing to launch the world’s first autologous T-cell therapy for solid tumors—a truly groundbreaking scientific achievement. Speed to market was critical to deliver life-changing care to patients who couldn’t wait. The vision was bold, but success required more than scientific and technological innovation—it demanded an agile, compliant, and patient-centric supply chain capable of matching the therapy’s complexity.
Bringing personalized medicine to market is never simple. Every patient represents a unique treatment journey, with data flowing between hospitals, labs, CROs, and manufacturing facilities.
The client faced a high-stakes challenge: design and deploy a fully operational supply chain solution in under six months. On top of this aggressive timeline, they needed:
Failure to get it right could lead to delays, rework, and patients waiting longer for critical treatments. Even minor lapses in regulatory compliance (such as with FDA standards) risked derailing the biotech firm’s broader vision for personalized medicine.
Hexaware partnered closely with the biotech team to design a solution that was fast, flexible, and future-ready.
Within six months, we:
From handling Out-of-Specification (OOS) lot retirements to supporting second manufacturing cycles, every capability, workflow, and system was designed with patients, regulators, and partners in mind.
The impact was transformative:
Ultimately, Hexaware gave the client what they needed most: confidence that their therapy could reach patients quickly, compliantly, and reliably.
Hexaware enabled a pioneering biotech to overcome the complex hurdles of cell & gene therapy commercialization. In just six months, we delivered an integrated, compliant, and patient-focused supply chain solution—accelerating market readiness, enhancing collaboration, and ensuring accuracy at every stage. Together, we helped bring breakthrough therapy closer to the patients who need it most.
Discover how Hexaware empowers life sciences and healthcare organizations to accelerate innovation, enhance compliance, and deliver better outcomes for patients worldwide. Explore our life sciences and healthcare solutions now.